Michel Detheux - 01 Sep 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
01 Sep 2021
Net transactions value
-$580,518
Form type
4
Filing time
03 Sep 2021, 20:01:00 UTC
Previous filing
31 Aug 2021
Next filing
27 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale $245,722 -8,684 -6.9% $28.30 117,005 01 Sep 2021 Direct F1, F2
transaction ITOS Common Stock Sale $318,574 -11,018 -9.4% $28.91 105,987 02 Sep 2021 Direct F1, F3
transaction ITOS Common Stock Sale $16,221 -550 -0.52% $29.49 105,437 02 Sep 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.64, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.38 to $29.35, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.42 to $29.51, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.